

27 **ABSTRACT**

28 *Staphylococcus aureus* is one of the most common pathogens isolated from the lungs of
29 people with cystic fibrosis (CF), but little is known about its ability to colonize this niche. We
30 performed a Tn-seq screen to identify genes necessary for *S. aureus* growth in media prepared
31 from *ex vivo* CF sputum. We identified 19 genes that were required for growth in all sputum
32 media tested and dozens more that were required for growth in at least one sputum medium.
33 Depleted mutants of interest included insertions in many genes important for surviving metal
34 starvation as well as the primary regulator of cysteine metabolism *cymR*. To investigate the
35 mechanisms by which these genes contribute to *S. aureus* growth in sputum, we quantified low-
36 molecular-weight thiols, nutrient transition metals, and the host metal-sequestration protein
37 calprotectin in sputum from 11 individuals with CF. In all samples, the abundance of calprotectin
38 exceeded nutrient metal concentration, explaining the *S. aureus* requirement for metal-
39 starvation genes. Further, all samples contain potentially toxic quantities of cysteine and
40 sufficient glutathione to satisfy the organic sulfur requirements of *S. aureus*. Deletion of the
41 cysteine importer genes *tcyA* and *tcyP* in the $\Delta cymR$ background restored growth to wild-type
42 levels in CF sputum, suggesting that the mechanism by which *cymR* is required for growth in
43 sputum is to prevent uncontrolled import of cysteine or cystine from this environment. Overall,
44 this work demonstrates that calprotectin and cysteine limit *S. aureus* growth in CF sputum.

45

46 **IMPORTANCE**

47 *Staphylococcus aureus* is a major cause of lung infections in people with cystic fibrosis
48 (CF). This work identifies genes required for *S. aureus* growth in this niche, which represent
49 potential targets for anti-Staphylococcal treatments. We show that genes involved in surviving
50 metal starvation are required for growth in CF sputum. We also found that the primary regulator
51 of cysteine metabolism, CymR, plays a critical role in preventing cysteine intoxication during
52 growth in CF sputum. To support these models, we analyzed sputum from 11 individuals with CF

- 53 to determine concentrations of calprotectin, nutrient metals, and low-molecular-weight thiols,
54 which have not previously been quantified together in the same samples.

55 INTRODUCTION

56 Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis
57 transmembrane conductance regulator (CFTR) ion channel, which normally transports chloride
58 ions into the extracellular space (1–3). CFTR dysfunction affects multiple organ systems, the
59 most clinically important of which is the respiratory tract. Impaired chloride transport by airway
60 epithelial cells leads to reduced mucus hydration, which severely impairs mucociliary clearance,
61 a key defense against respiratory pathogens (4, 5). People with CF (pwCF) are especially
62 vulnerable to chronic lung infection by a range of pathogens, the most common and best-
63 studied of which are *Pseudomonas aeruginosa* and *Staphylococcus aureus* (6).

64 *S. aureus* is typically the earliest microbe detected in airway secretions of children with
65 CF (7). For the past 20 years it has overtaken *P. aeruginosa* as the most prevalent bacterial
66 species in the lungs of pwCF, with over 60% of individuals culture-positive for *S. aureus* (7). The
67 subset of *S. aureus* infections caused by methicillin-resistant *S. aureus* (MRSA) has also been
68 steadily increasing (7). *S. aureus* lung infections lead to heightened inflammation, frequent
69 hospitalizations, reduced lung function which can become permanent, and lower overall
70 survival; each of these outcomes is further worsened if the infection is caused by MRSA (8–10).
71 These infections are typically chronic and difficult to treat with traditional antibiotics (11).
72 Additionally, while highly-effective modulator treatments restore CFTR function, there are
73 significant barriers to access for these treatments, including the high cost and lack of availability
74 in many countries (12). Moreover, modulators do not eradicate bacterial infection in most pwCF
75 (13). Despite the prevalence and importance of *S. aureus* infections in pwCF, surprisingly little is
76 known about how *S. aureus* grows in this niche.

77 Modeling CF lung infection in research settings has many challenges. Animal models of
78 CF are available in a wide range of species, including zebrafish, mice, rats, ferrets, pigs, and
79 sheep (14). Each of these models is useful and appropriate for certain applications, but all are
80 imperfect. For example, mice with *Cftr* mutations do not spontaneously develop lung disease,

81 nor are they particularly susceptible to bacterial infection, making them ill-suited to model *S.*
82 *aureus* lung infections (15). Only the porcine and ferret models recapitulate the lung pathology
83 and impaired bacterial clearance observed in humans with CF, although these are both
84 impractical for most research applications (16, 17). Airway epithelial tissue culture models have
85 been successful in drug development applications, but are less appropriate for microbiological
86 studies due to the absence of key aspects of infection such as mucus and immune cells (18).

87 An alternative to animal or tissue culture models is an *ex vivo* culture model using mucus
88 expectorated from the lower airways, known as sputum. In the CF lung environment, *S. aureus*
89 typically localizes within the mucus rather than on epithelial surfaces (19). This characteristic
90 makes *S. aureus* a particularly good candidate for the *ex vivo* sputum culture model. *Ex vivo*
91 models of infection also have the advantage of eliminating the use of animals.

92 With recent advancements in highly-effective CFTR modulator therapies, fewer pwCF
93 are able to expectorate sputum. To overcome the increasing scarcity of *ex vivo* CF sputum,
94 there has been increased interest in developing a fully synthetic *in vitro* model of growth in CF
95 sputum. One such *in vitro* model is synthetic cystic fibrosis sputum medium (SCFM), the
96 composition of which is based on thorough chemical analyses of CF sputum samples (20).
97 SCFM has been thoroughly validated for modeling *P. aeruginosa* growth in CF sputum, but less
98 data are available regarding its suitability for modeling the growth of *S. aureus* or other microbes
99 (20–22).

100 In this study, we used a forward genetic screening approach to identify genes required
101 for *S. aureus* growth in *ex vivo* CF sputum and SCFM. We also explored the heterogeneity of *S.*
102 *aureus* growth in independent sputum samples and the *S. aureus* genes required for growth in
103 each. The results of our genetic analysis were contextualized by quantifying key components
104 that influence bacterial growth, including calprotectin, nutrient metals, and low-molecular-weight
105 thiols, in multiple sputum samples. Overall, this work presents a comprehensive analysis of *S.*
106 *aureus* growth in CF sputum and the constituents of sputum that impact this growth.

107 RESULTS

108

109 Tn-seq identifies genes required for growth in CF sputum media

110 To identify *S. aureus* genes required for growth in CF sputum, we performed a
111 transposon-sequencing (Tn-seq) screen using media derived from the sputum of four pwCF. We
112 generated a high-density transposon library containing a transposon insertion approximately
113 every 20 base pairs in the laboratory MRSA strain JE2, derived from USA300 LAC (23, 24).
114 Sputum media were prepared by mechanically homogenizing CF sputum at a concentration of
115 10% (w/v) in Staphylococcal minimal medium (SMM) with no carbon source provided (25). We
116 confirmed the ability of each sputum medium to support the growth of *S. aureus* before
117 proceeding with Tn-seq (data not shown). To probe both a core set of genes generally required
118 for growth in sputum as well as heterogeneity between different samples, we inoculated the
119 library into four individual sputum media as well as a medium composed of all four media pooled
120 at equal volumes. As reference conditions, the library was grown in tryptic soy broth (TSB) or
121 synthetic CF sputum medium (SCFM3), a medium developed and validated to model
122 *Pseudomonas aeruginosa* growth in CF sputum (20, 21). The abundance of each mutant in
123 sputum media and SCFM3 after 16 hours of growth was compared to that in TSB (Table S1).
124 Tn-seq hits were defined as genes whose mutants were either depleted or enriched by at least
125 two-fold in any sputum medium or in SCFM3 compared to TSB with an adjusted *p*-value of less
126 than 0.05.

127 We first sought to determine the extent of overlap between the 75 to 116 hits identified in
128 each individual sputum medium (Fig. 1A and Fig. S1A). The largest set included 39 genes that
129 were common to all four media, suggesting that despite gross differences in appearance and
130 other observable qualities, CF sputa from different individuals impose similar selective
131 pressures on *S. aureus*. Of the set of 39 genes common to all four media, mutants in 19 genes
132 were depleted, suggesting these genes are required for growth or survival in sputum (Table 1).


133 This analysis also demonstrates that while there is a core set of genes that are important for
134 growth in CF sputum, there is also appreciable heterogeneity among the individual sputum
135 samples.

136 To complement the set analysis, we next sought to cluster genes according to their
137 importance or dispensability for growth in each sputum medium. A heatmap was generated
138 comparing results from each individual sputum medium and pooled sputum medium to those
139 from the TSB reference condition using an ANOVA analysis (Fig. 1B, Fig. S1B, and Table S2).
140 This clustering strategy revealed patterns among significant genes. For example, mutants in
141 *copA*, *rpsN2*, and *cntE* were all strongly depleted after growth in individual sputum media
142 samples A and B as well as the pooled medium, but were neither enriched nor depleted in
143 media from samples C and D. This suggests that a stressor present in samples A and B
144 dominated the pooled medium even when combined with samples C and D. Mutants in the two-
145 component system *graRS* and the primary member of its regulon, the adjacent operon *vraGF*,
146 were all depleted in media A and B, enriched in media C and D, and neither enriched nor
147 depleted when all four media were pooled. This pattern may indicate some opposing factors in
148 samples A and B compared to C and D that are masked when combined. These emerging
149 patterns highlight the power of analyzing individual sputum media, as these genes would not
150 have been identified by only analyzing Tn-seq data from pooled sputum.

151 **TABLE 1. Hits significantly depleted in all four individual sputum media.** Log₂fold-change (FC)
 152 in pooled media is also indicated. Genes without annotations are identified by their SAUSA300
 153 gene locus tags.

Gene	Function	log ₂ FC in sputum medium				
		A	B	C	D	Pool
<i>sirB</i>	Iron acquisition	-2.51	-2.26	-1.13	-1.32	-2.53
<i>nanE</i>	Sialic acid metabolism	-1.59	-1.72	-4.89	-2.20	-1.94
<i>fhuA</i>	Iron acquisition	-2.66	-2.44	-1.14	-2.47	-2.16
<i>ccpE</i>	Catabolite control protein E	-1.09	-1.01	-1.98	-1.37	-1.91
<i>gudB</i>	Glutamate dehydrogenase	-1.20	-1.29	-1.95	-1.45	-1.69
<i>ylaN</i>	Candidate Fur antagonist	-2.42	-2.54	-2.55	-2.64	-2.45
<i>sdhC</i>	Succinate dehydrogenase complex	-1.26	-1.49	-2.16	-1.77	-1.23
<i>sdhA</i>	Succinate dehydrogenase complex	-1.25	-1.71	-2.51	-2.05	-1.22
<i>sdhB</i>	Succinate dehydrogenase complex	-1.19	-1.75	-2.20	-1.95	-1.61
<i>fakA</i>	Fatty acid kinase	-1.89	-1.39	-1.80	-1.72	-1.23
<i>sucB</i>	Succinyl-CoA synthesis	-1.39	-1.53	-1.92	-1.75	-1.39
<i>sucA</i>	Succinyl-CoA synthesis	-1.14	-1.29	-1.21	-1.14	-1.26
<i>cymR</i>	Cysteine metabolism regulator	-1.76	-1.57	-1.39	-2.00	-1.91
<i>hemL</i>	Heme biosynthesis	-1.17	-1.25	-1.68	-1.76	-1.68
<i>perR</i>	Oxidative stress response	-1.30	-1.13	-2.81	-1.38	-0.92
2100	Putative lytic regulatory protein	-1.12	-1.47	-1.81	-1.43	-1.57
<i>salA</i>	Putative chromosome partitioning protein	-1.79	-2.01	-2.62	-2.60	-2.12
<i>mntE</i>	Manganese exporter	-4.42	-4.17	-4.77	-4.35	-4.36
<i>betB</i>	Betaine aldehyde dehydrogenase	-1.11	-1.28	-1.17	-1.06	-1.06

154



156 **Figure 1. Analysis of Tn-seq results. A)** UpSet plot showing the extent of overlap of hits
157 between different CF sputum media. Hits were defined as genes that were significantly enriched
158 or depleted by at least 2-fold in sputum medium compared to TSB. Significance was determined
159 using the resampling method in TRANSIT and *p*-values were adjusted for multiple comparisons
160 using the Benjamini-Hochberg procedure. Hits that were enriched in one or more samples but
161 depleted in one or more other samples were not counted as overlapping. **B)** Heatmap displaying
162 the top 50 most significant genes by one-way ANOVA with TSB as the reference condition.

163

164 **Genes identified by Tn-seq are required for growth in CF sputum in monoculture**

165 From the analyses described above, we selected a panel of nine genes span a variety of
166 pathways for further study to investigate multiple mechanisms by which CF sputum imposes
167 selective pressure on *S. aureus* (Table 2). First, genes encoding metabolic proteins were of
168 particular interest. The transcription factor CymR is the master regulator of cysteine metabolism
169 in *S. aureus*, suggesting a role for cysteine metabolism during growth in CF sputum (26–28).
170 NanE and PruA belong to pathways for metabolizing sialic acid and proline, respectively (29,
171 30). These two nutrients are present at high concentrations in CF sputum and likely serve as
172 nutrient sources that support bacterial growth (20, 31). MntE and CopA are manganese and
173 copper efflux pumps, respectively, that protect cells from metal intoxication (32, 33). That these
174 efflux pumps were required suggests that manganese and copper may be present at toxic levels
175 in CF sputum. Next, we selected genes that suggest nutrient metals are limited in CF sputum.
176 Mutants lacking CntE, the exporter for the general metallophore staphylopin, are impaired for
177 metal acquisition (34). In addition, $\Delta cntE$ mutants accumulate a toxic excess of staphylopin in
178 the cytosol, which is more detrimental during zinc starvation than the lack of zinc (35). To
179 determine whether the growth defect of the $\Delta cntE$ mutant was due to its zinc acquisition defect
180 or due to staphylopin toxicity, we also evaluated a mutant deactivated for *cntA*, which was not
181 a hit in the Tn-seq analysis. Mutants lacking *cntA* cannot import staphylopin, so these mutants

182 exhibit the same metal acquisition defect as $\Delta cntE$ mutants but do not experience toxic
183 staphylopine buildup (36). Finally, *rpsN2* encodes an alternative RpsN ribosomal protein which
184 is zinc-independent and required during zinc starvation (37). Mutants lacking the genes-of-
185 interest were constructed by allelic exchange or transducing a disrupting transposon from the
186 Nebraska Transposon Mutant Library into a clean JE2 background.

187 To validate the Tn-seq screen, we incubated each mutant individually in TSB or a new
188 pooled sputum medium for 12 hours and measured growth by enumerating colony forming units
189 (CFU). To examine whether the identified genes were generalizable to different patient samples,
190 the new pooled sputum medium combined two of the sputum samples used in the Tn-seq
191 (Sputum C and Sputum D) with two additional samples (Sputum 7 and Sputum 8). To minimize
192 the effects of components other than sputum on bacterial growth, these four sputum media were
193 prepared in SCFM buffered-base rather than in SMM. All of the mutants grew similarly to the
194 parental strain in TSB (Fig. 2A). In sputum medium, cell density of the wild-type (WT) strain
195 increased approximately 100-fold in 12 hours, while most mutants exhibited growth defects
196 relative to WT, three of which were statistically significant: *cymR*, *cntE*, and *rpsN2* (Fig. 2B).
197 These results demonstrate the robustness of the Tn-seq screen, as many mutants displayed
198 growth defects in sputum in monoculture, as well as in sputum from patients beyond those in
199 the original screen.


200 **Table 2. Genes selected for further study.**

Gene	Function/pathway	Condition(s) identified
<i>cymR</i>	Cysteine metabolism regulator	Sputum A-D and pooled
<i>ylaN</i>	Candidate Fur antagonist	Sputum A-D and pooled
<i>nanE</i>	Sialic acid metabolism	Sputum A-D and pooled
<i>cntE</i>	Staphylopine exporter	Sputum B, D, and pooled
<i>cntA</i>	Staphylopine importer	None (see text)
<i>mntE</i>	Manganese exporter	Sputum A-D and pooled
<i>pruA</i>	Proline metabolism	Sputum B-D and pooled
<i>copA</i>	Copper efflux pump	Sputum B, D, and pooled
<i>rpsN2</i>	Zn ²⁺ -independent alternative S14 ribosomal protein	Sputum B, D, and pooled

201

202

203



204

205 **Figure 2. Bacterial density after 12 hours of growth.** Approximately 2×10^5 CFU of each
 206 strain was inoculated and incubated for 12 hours in 100 μ L of **A)** TSB or **B)** pooled CF sputum
 207 media. Data represent three independent experiments combined. Two asterisks (**) indicate $p <$
 208 0.01 as measured by Brown-Forsythe & Welch One-way ANOVA with Dunnett's multiple
 209 comparison correction on log-transformed CFU values and n.s. indicates $p >$ 0.05 compared to
 210 WT.

211

212


213 **Calprotectin restricts metal availability in sputum**

214 Host sequestration of essential nutrient transition metals has long been appreciated as a
215 key defense against bacterial infections, in a process known as nutritional immunity (38–40).
216 Many of the hits we identified by Tn-seq are required for surviving metal starvation, suggesting
217 that CF sputum is also devoid of these key nutrients. Mutants that lacked *cntE* or *rpsN2*, genes
218 known to be required to survive zinc starvation, exhibited significant growth defects in pooled
219 CF sputum medium (41, 42). Several other genes identified by Tn-seq as required for growth in
220 CF sputum, including *ylaN*, *fhuA*, and *sirB*, are necessary during iron limitation (43–45). In
221 contrast, *copA*, which encodes a copper efflux pump, was important in a subset of sputum
222 media, suggesting that copper availability may impact *S. aureus* growth more in some CF sputa
223 than in others (33).

224 To investigate the importance of metal starvation during *S. aureus* growth in CF sputum,
225 we quantified total transition metals in sputum samples from 11 pwCF using inductively coupled
226 plasma mass spectrometry (ICP-MS). Copper levels ranged from 164 to 654 nM, with an
227 average of 325 nM (Fig. 3). Iron was generally more abundant, with concentrations ranging from
228 0.57 to 3.61 μM and an average of 1.61 μM . Zinc was the most abundant transition metal,
229 ranging from 0.61 to 6.27 μM and an average of 2.59 μM . While SCFM contains neither copper
230 nor zinc, it does contain iron at a concentration of 3.6 μM , comparable to the concentrations we
231 measured in sputum. Additional elements are quantified in Figure S3.

232 A host protein that is particularly important in nutritional immunity is calprotectin, a dimer
233 of calcium-binding proteins S100A8 and S100A9, which can bind and sequester a spectrum of
234 transition metals with affinities in the picomolar to nanomolar range (40, 46–48). Calprotectin is
235 primarily produced by neutrophils and thus is often abundant at sites of infection, including
236 chronic infections, such as those occurring in the lungs of pwCF (49). As ICP-MS quantifies all
237 metals in a sample, whether or not they are protein-bound, we contextualized metal availability

238 and quantified calprotectin by ELISA in the same sputum samples. In all 11 cases, calprotectin
239 was in significant excess relative to any metal we quantified (Fig. 3). These observations
240 suggest the simple model that the mechanism by which *cntE* and *rpsN2* are required for growth
241 in CF sputum is that mutants lacking these genes are unable to survive metal starvation
242 imposed by calprotectin.




243
244 **Figure 3. Quantification of calprotectin, iron, zinc, and copper in CF sputum.** Total metals
245 were quantified by ICP-MS while calprotectin was quantified by ELISA. Calprotectin
246 quantifications are the mean and standard deviation (SD) of at least two independent assays,
247 each performed in technical duplicate. The four samples used in validation medium in Fig. 2 are
248 indicated in bold. Samples B and D were also used in Tn-seq.

249 250 Cysteine concentrations in sputum

251 In addition to *cntE* and *rpsN2*, *cymR* was also required for *S. aureus* growth in CF
252 sputum, yet the importance of *cymR* in this growth niche cannot adequately be explained by
253 calprotectin-dependent metal sequestration. CymR is a redox-sensitive transcription factor
254 whose regulon consists of genes involved in metabolizing and importing organic sulfur sources,

255 particularly cysteine (26–28). Deletion of *cymR* is known to sensitize *S. aureus* to excess
256 cysteine, and thus, we hypothesized that the growth defect of the $\Delta cymR$ mutant in sputum may
257 be caused by excess cysteine (26). To address this hypothesis, we quantified the low-
258 molecular-weight (LMW) thiols cysteine and glutathione (GSH) using an isotope-dilution LC-MS
259 workflow in the same 11 sputum samples in which we quantified metals and calprotectin. Patient
260 samples were not stored in specific anaerobic conditions, and therefore the ratios of oxidized
261 (cystine and glutathione disulfide, GSSG) to reduced thiols (cysteine and GSH) present in the
262 samples at the time of expectoration could not be determined. Rather, we quantified the total
263 amounts of each thiol after treating these samples with a reducing agent. The sputum samples
264 contained between 11 and 296 μM GSH, higher than the published quantity of approximately 10
265 μM (Fig. 4) (50). This concentration of GSH alone is sufficient to fulfill the organic sulfur
266 requirements of *S. aureus* (51). Total cysteine concentrations in CF sputum ranged from 65 to
267 3350 μM , and 10 of 11 samples surprisingly contained a higher concentration of cysteine than
268 the 160 μM present in SCFM (Fig. 4) (20). It is therefore plausible that cysteine concentrations
269 in this range could be toxic to the $\Delta cymR$ mutant during growth in CF sputum.
270




271

272 **Figure 4. Quantification of thiols in CF sputum.** The same 11 sputum samples from Figure 3
273 were analyzed by LC-MS for thiol abundance after treatment with a reducing agent. Data are
274 the mean and SD of triplicate measurements. Samples used in validation medium are indicated
275 in bold.

276 **Excess cysteine import is toxic during growth in CF sputum**

277 To investigate the role of *cymR* during growth in CF sputum, we took a genetic approach
278 and employed an *in vitro* synthetic sputum model, as manipulating the components of *ex vivo*
279 sputum is not feasible. We used SCFM1 for these experiments, which differs from SCFM3
280 primarily by omitting mucin and DNA, while including all amino acids, including cysteine, at the
281 same concentrations as SCFM3 (21). The absence of mucin renders SCFM1 optically clear,
282 enabling bacterial growth to be measured by optical density. To test the hypothesis that the
283 relative growth defect of the $\Delta cymR$ mutant in CF sputum is due to cysteine toxicity, we grew
284 WT *S. aureus*, the $\Delta cymR$ mutant, and a *cymR* genetic complement in SCFM1 (20). The $\Delta cymR$
285 mutant and its complement grew similarly to WT in TSB (Fig. 5A). However, the $\Delta cymR$ mutant
286 displayed reduced growth in SCFM1 compared to WT, but growth was restored when *cymR* was
287 reintroduced on a plasmid under the control of its native promoter (Fig. 5B). Interestingly, the
288 $\Delta cymR$ mutant did not exhibit a growth defect when grown in TSB supplemented with 2 mM
289 cysteine, indicating that the observed phenotype in SCFM1 varies depending on nutritional
290 context (Fig. 5C). The concentration of cysteine in SCFM is 160 μ M, which is a very
291 conservative estimate of cysteine availability in CF sputum when compared with our thiol
292 profiling data (Fig. 4). It is striking that cysteine is toxic to the $\Delta cymR$ mutant in SCFM1 even at
293 this low concentration, but not at the high concentration of 2 mM in TSB.

294 We then tested whether this growth defect was due to excess organic sulfur in general,
295 or if it was specifically caused by cysteine. As *S. aureus* is a cysteine auxotroph, the cysteine in
296 SCFM1 was replaced with the alternate organosulfur source N-acetylcysteine (NAC), which is
297 imported by the same mechanism as cysteine (52). The $\Delta cymR$ mutant is able to grow similarly
298 to WT in SCFM1 containing NAC in place of cysteine (Fig. 5D), suggesting that the growth
299 defect of the $\Delta cymR$ mutant in SCFM1 is specifically due to cysteine.



300

301 **Figure 5. CymR-dependent growth kinetics in the presence of cysteine or N-**

302 **acetylcysteine.** Growth kinetics in **A)** TSB, **B)** SCFM1, **C)** TSB supplemented with 2 mM

303 cysteine, and **D)** SCFM1 containing N-acetylcysteine (NAC) in place of cysteine. Data are the

304 mean and standard deviation (SD) of three independent experiments. Asterisk (*) indicates $q <$

305 0.05 from 160 – 390 min, as measured by Welch's T-test with two-stage step-up multiple

306 comparison correction on OD₆₀₀ measurements.

307

308 Two of the direct repression targets of CymR are: *i)* *tcyABC*, encoding an ATP-binding

309 cassette (ABC) transporter known to import cysteine, cystine, and NAC, and *ii)* *tcyP*, encoding a

310 high-affinity permease that also imports cysteine, cystine, and NAC (52). As both *tcyABC* and

311 *tcyP* are strongly upregulated in the absence of CymR, we hypothesized that uncontrolled


312 cysteine import via TcyABC and/or TcyP was responsible for the growth defect of the $\Delta cymR$

313 mutant in SCFM1 (26). To test this hypothesis, we deleted *tcyA* and *tcyP* individually and in

314 combination with deletion of $\Delta cymR$. When grown in SCFM1, in which the only organic sulfur

315 source is cysteine, the $\Delta cymR$ strain had a pronounced growth defect, as observed previously.
316 Neither the $\Delta tcyA \Delta tcyP$ double mutant nor the $\Delta cymR \Delta tcyA \Delta tcyP$ triple mutant were able to
317 grow, supporting previous reports that TcyABC and TcyP are the only cysteine importers in *S.*
318 *aureus* (Fig. 6A). Importantly, single $\Delta tcyA$ and $\Delta tcyP$ mutants grew similarly to WT in all
319 conditions and deleting *tcyA* in the $\Delta cymR$ background partially rescued growth in the presence
320 of cysteine (Fig. S2). When cysteine was substituted for equimolar organic sulfur in the form of
321 GSH, which is imported independently of TcyABC and TcyP, all strains grew similarly to WT (Fig.
322 6B) (51, 52). In the presence of GSH to support the growth of mutants lacking cysteine
323 importers, cysteine remained toxic to the $\Delta cymR$ mutant (Fig. 6C). Growth of $\Delta cymR$ was
324 restored to WT levels when *tcyA* and *tcyP* were deleted in this background, even with the lowest
325 concentration of GSH present in sputum (Fig. 6D). These results support the model that the
326 $\Delta cymR$ mutant exhibits a growth defect in SCFM1 due to excess import of cysteine via TcyABC
327 and TcyP.

328 After determining the mechanism by which the $\Delta cymR$ mutant is attenuated for growth in
329 the synthetic sputum model, we tested whether this same mechanism was responsible for the
330 growth defect of the $\Delta cymR$ mutant in *ex vivo* CF sputum. We grew the $\Delta tcyA \Delta tcyP$ double
331 mutant and the $\Delta cymR \Delta tcyA \Delta tcyP$ triple mutant in the same pooled CF sputum medium that
332 was used to test growth in monoculture for 12 hours. When *tcyA* and *tcyP* were deleted in the
333 WT background, there was no difference in growth compared to WT (Fig. 6E). However, when
334 both *tcyA* and *tcyP* were deleted in the $\Delta cymR$ background, growth was restored to WT levels.
335 These data suggest that the $\Delta cymR$ mutant grows poorly in CF sputum due to excess cysteine
336 import by TcyABC and TcyP.



337

338 **Figure 6. The role of cysteine importers in cysteine toxicity of $\Delta cymR$.** A-D) Growth kinetics
339 of bacterial strains in SCFM1 containing the indicated sulfur source: A) cysteine, B) GSH, C)
340 equimolar cysteine and GSH, D) cysteine and minimal GSH. Data are the mean and standard
341 deviation (SD) of four independent experiments. E) Bacterial density 12 hours after inoculation
342 in pooled sputum medium. Data from WT and $\Delta cymR$ strains are identical to those found in
343 Figure 3. Two asterisks (**) indicate $p < 0.01$ as measured by Brown-Forsythe & Welch One-
344 way ANOVA with Dunnett's multiple comparison correction on log-transformed CFU values.

345 **DISCUSSION**

346 In this study we investigated the environment experienced by *S. aureus* in the CF lung,
347 beginning with a Tn-seq screen to determine the *S. aureus* genes required in *ex vivo* CF
348 sputum. By comparing four unique sputum samples as well as a pooled sputum medium, we
349 identified 19 genes that were required for *S. aureus* growth in all sputum media and many more
350 genes that were required for growth in at least one sputum medium. Mutants significantly
351 depleted from all sputum samples include insertions in metabolic genes, those necessary for
352 metal homeostasis, and the regulator of cysteine metabolism *cymR*. To decipher the roles of
353 these genes in the unique environment of CF sputum, we quantified transition metals, the host
354 protein calprotectin, and LMW thiols in sputum from 11 individuals. These analyses revealed
355 that calprotectin was in stoichiometric excess relative to the total metals present, suggesting
356 that bioavailable iron, copper, and zinc are substantially lower than the total measured
357 concentrations (46–48). We also measured much more cysteine and GSH in sputum than
358 previously appreciated. Together, results from this study provide a holistic understanding of the
359 environment encountered by *S. aureus* during chronic infection of the CF lung and the genes it
360 requires to survive and replicate in this milieu.

361 We performed Tn-seq in four unique media, each prepared from an independent CF
362 sputum sample. This approach allowed us not only to identify genes that are generally required
363 for growth in CF sputum, but to assess the extent to which the genetic requirements for growth
364 are similar or different in distinct individuals. Previous studies, primarily in *P. aeruginosa*, used
365 pooled CF sputa from multiple donors to minimize the effects of heterogeneity between
366 samples. However, comparing Tn-seq results from individual sputum revealed phenotypes that
367 were masked in the pooled medium, highlighting the power of exploring heterogeneity as a
368 complement to studying generalizable phenotypes. For example, mutants of *graRS* and *vraGF*
369 were enriched in two sputum media and depleted in two sputum media, while there was no
370 major enrichment or depletion in the pooled medium. This phenotypic pattern suggests that

371 there are important roles for *graRS* and *vraGF* during growth in CF sputum that likely differ from
372 person-to-person.

373 Sputum heterogeneity may explain why some of the genes we selected for validation
374 studies did not exhibit growth defects in monoculture, such as *nanE*, involved in the metabolism
375 of sialic acid (29). Mucins are heavily decorated with sialic acid moieties and thus, sialic acid is
376 abundant in CF sputum (53). Although *S. aureus* is unable to liberate sialic acid from mucin,
377 other bacterial species commonly found in the CF lung, including *Schaalia odontolytica*,
378 *Prevotella melaninogenica*, and *Streptococcus* spp., are capable of doing so (54–58). The
379 requirement for *nanE* in some sputum media but not others could indicate sialic acid cross-
380 feeding by other bacterial species present in those sputum samples.

381 One of the most prominent gene signatures we observed in the Tn-seq results was that
382 of metal homeostasis. Mutants in genes involved in iron uptake and heme biosynthesis,
383 including the *sir* and *fhu* operons as well as *hemL*, were significantly depleted in all four
384 individual sputum media. Additionally, we identified the zinc-independent ribosomal protein
385 encoded by *rpsN2* and the staphylopine exporter *cntE* as required for growth in sputum.
386 Together, these hits suggest that *S. aureus* experiences metal starvation in CF sputum.
387 Somewhat paradoxically, we also identified genes important for detoxifying metal stress,
388 including the manganese and copper exporters encoded by *mntE* and *copA*, respectively.
389 Identifying multiple metal homeostasis genes prompted us to quantify the transition metals
390 present in sputum.

391 Host sequestration of essential nutrient transition metals has long been appreciated to
392 serve as a key defense against bacterial pathogens, a phenomenon known as nutritional
393 immunity (38–40). Calprotectin is an abundant host protein that mediates nutritional immunity by
394 binding and sequestering transition metals; thus, measuring calprotectin is critical for
395 contextualizing metal availability (40, 46). Our analysis of calprotectin and nutrient metal
396 concentrations in CF sputum revealed that calprotectin was far more abundant than copper,

397 iron, or zinc in every sample tested. To our knowledge, sputum samples have not previously
398 been analyzed for concentrations of both calprotectin and nutrient metals. ICP-MS quantifies all
399 metals in a sample, whether or not they are protein-bound. Our data measuring the relative
400 quantity of calprotectin suggests that the metals may not be accessible to bacteria.

401 The excess of calprotectin relative to nutrient metals in CF sputum suggests that $\Delta cntE$
402 and $\Delta rpsN2$ mutants exhibited significant growth defects in CF sputum medium due to metal
403 starvation imposed by calprotectin. Loss of *cntE* prevents export of the metallophore
404 staphylopin, which is primarily used for zinc acquisition (41). Sensitivity of $\Delta cntE$ to zinc
405 starvation is at least partially due to toxic accumulation of staphylopin in the cytosol rather than
406 the inability to acquire zinc (34, 35). To test whether the growth defect of the $\Delta cntE$ mutant is
407 due to zinc starvation or staphylopin toxicity, we investigated the growth of a *cntA::Tn* mutant,
408 which is impaired for staphylopin import (41). The mutant lacking *cntA* (*cntA::Tn*) exhibited an
409 approximately 10-fold growth defect in CF sputum medium ($p = 0.15$). A possible explanation for
410 this observation is that metal starvation plays a role in the growth defect of the $\Delta cntE$ mutant but
411 that staphylopin toxicity may also contribute.

412 Recent studies have similarly underscored the selective pressure that calprotectin
413 imposes on bacteria. For example, Tn-seq performed on *S. aureus* growing in TSB containing
414 calprotectin identified genes that overlap strikingly with our CF sputum Tn-seq results, including
415 the *cnt* operon and *rpsN2* (59). That is, simply adding calprotectin to rich medium is sufficient to
416 recapitulate many phenotypes observed in CF sputum medium. Additionally, it was noted that
417 adding calprotectin to SCFM improves the accuracy of SCFM in recapitulating the
418 transcriptional landscape of *P. aeruginosa* during growth in CF sputum (60). The strong effect of
419 calprotectin on *S. aureus* also likely explains why there was little overlap in our Tn-seq screen in
420 SCFM3, which does not contain calprotectin, and our results in CF sputum. Our Tn-seq data are
421 also interesting in the context of the *S. aureus* transcriptional response during growth in CF
422 sputum. Many of the genes we identified as essential for growth in CF sputum media are also

423 upregulated in *S. aureus* isolated from CF sputum samples, including the *cnt* operon, *nanE*, and
424 *copA* (22). Ibberson and Whiteley mapped clinical isolate reads to a reduced core genome of
425 1,960 genes, so neither *rpsN2* nor *cymR* were analyzed; however, *tcyA* and *tcyP* were
426 downregulated, consistent with our *cymR* analysis (22).

427 A $\Delta cymR$ deletion mutant exhibited a significant growth defect in CF sputum, which
428 cannot be explained by calprotectin-mediated metal starvation and instead suggests a role for
429 cysteine toxicity during growth in CF sputum. To explore whether cysteine could be present at
430 toxic levels in CF sputum, we quantified the total amount of cysteine and GSH in the same
431 samples in which we quantified calprotectin and metals. We found that cysteine concentrations
432 ranged from 65 – 3,350 μM and GSH concentrations ranged from 11 - 296 μM , much higher
433 quantities of both thiols than previously reported (20, 50). Excess cysteine has long been known
434 to cause toxicity in bacteria, by either metabolic or oxidative stress (61–63). Our genetic data
435 and thiol profiling results together suggest that in the absence of *cymR*, *S. aureus* likely imports
436 a toxic amount of cysteine, causing attenuated growth in CF sputum. The exact mechanism by
437 which cysteine is toxic to *S. aureus* in CF sputum is yet to be determined. The simplest
438 explanation is that excess intracellular cysteine or oxidized cystine interacts with intracellular
439 iron to inflict oxidative damage and attenuate growth, similar to what was shown in *E. coli* (63).
440 However, we do not favor this hypothesis due to the fact that cysteine remained toxic to the
441 $\Delta cymR$ mutant even in the presence of equimolar GSH, a potent antioxidant. Further, our thiol
442 profiling data showed that GSH is present in CF sputum in high enough concentrations to fulfill
443 the organic sulfur requirements of *S. aureus* without the need to import any free cysteine at all
444 (51). An alternative hypothesis is that dysregulated cysteine import perturbs metabolic flux,
445 leading to reduced growth. The dispensability of cysteine importers TcyABC and TcyP could
446 suggest that *S. aureus* does not primarily use cysteine as a source of nutrient sulfur during
447 growth in CF sputum as it does in other niches, including systemic infection (52). Avoiding free

448 cysteine import altogether when other organosulfur sources are available could be a protective
449 strategy against cysteine intoxication.

450 Although the manganese efflux pump *mntE* was identified by Tn-seq as important in all
451 sputum media, the *mntE*::Tn mutant did not exhibit a growth defect in monoculture. This
452 discrepancy is likely due to technical differences in the preparation of sputum medium. For Tn-
453 seq experiments, sputum was homogenized in SMM, which contains manganese, while the
454 sputum media used for validation studies were prepared in buffered base without manganese
455 (20, 25). This hypothesis is supported by the fact that *mntE* was also identified as required for
456 growth in SMM containing glucose in a pilot Tn-seq screen (data not shown). Additionally, the
457 concentration of Mn (21 – 361 nM) we detected in sputum is not likely to cause toxicity (64, 65,
458 32). Mutants in the remaining two genes, *ylaN* and *pruA*, grew poorly compared to WT in
459 monoculture but these growth defects were not statistically significant. This may be a result of
460 the technical limitations of this growth model. WT *S. aureus* only replicates approximately 100-
461 fold in sputum medium, so minor or variable growth defects are difficult to detect statistically,
462 though they may be biologically relevant.

463 While we focused on genes required for growth in CF sputum, our Tn-seq screen also
464 identified several mutants that were enriched in all four sputum media, indicating that these
465 genes are actually detrimental to *S. aureus* growth in sputum. Most notably, transposon mutants
466 in the *rsbUVW-sigB* operon were enriched across all of the sputum media. SigB is the general
467 stress response sigma factor in *S. aureus*, and RsbU, RsbV, and RsbW are posttranslational
468 regulators of SigB (66, 67). This finding is particularly interesting because this operon is known
469 to accumulate inactivating mutations during long-term colonization of the CF lung (68). It has
470 been hypothesized that isolates deficient in the general stress response emerge during long-
471 term colonization due to their reduced virulence and, consequently, reduced immunogenicity
472 (68). However, these genes were identified as hits in all four sputum media in the absence of an

473 active immune response, suggesting that inactivation of the general stress response in *S.*
474 *aureus* instead confers a general growth advantage in CF sputum.

475 In summary, we found that despite heterogeneity between samples, there exists a core
476 set of genes required for growth in CF sputum. Many of these genes are involved in surviving
477 metal starvation, which we propose is imposed by the high concentration of calprotectin present
478 in CF sputum relative to available nutrient metals. We also establish that cysteine toxicity is a
479 calprotectin-independent source of stress on *S. aureus* growing in CF sputum. These new
480 insights into *S. aureus* growth in CF sputum fill an important gap in our understanding of how
481 this key pathogen is able to establish and maintain infections in the CF lung environment.

482 MATERIALS AND METHODS

483

484 Bacterial strains and growth conditions

485 Bacterial strains used in this study are listed in Table S3. All *S. aureus* strains were
486 cultivated in tryptic soy broth (TSB, BD Bacto) at 37 °C with aeration, unless otherwise
487 indicated. All *E. coli* strains were grown in Miller's lysogeny broth (LB) at 37 °C, with aeration.
488 Plasmids were introduced into *E. coli* by chemical transformation and into *S. aureus* by
489 electroporation. Antibiotics and additives (Sigma) were used at the following concentrations
490 where appropriate: kanamycin, 50 µg/mL; chloramphenicol, 10 µg/mL (rich media) or 2.5 µg/mL
491 (sputum media); erythromycin, 1 µg/mL; X-gal, 40 µg/mL. For all synthetic CF sputum medium
492 (SCFM1 and SCFM3) experiments, SCFM was prepared as previously described with the
493 exception that iron sulfate (FeSO₄) was omitted to recapitulate observed metal scarcity in CF
494 sputum (20, 21).

495

496 Cloning and mutant construction

497 Plasmids, phages, and oligonucleotides used in this study are listed in Tables S4 and
498 S5. Phage φ11:FRT was a gift from Timothy Meredith.(24) Plasmid pIMAY*-Z was constructed
499 from pIMAY* and pMUTIN4. Plasmid pIMAY* was a gift from Angelika Gründling (Addgene
500 plasmid #121441). Plasmid pMUTIN4 was obtained from the Bacillus Genetic Stock Center
501 (BGSC; catalog #ECE139).

502 The Nebraska Transposon Mutant Library (NTML) was provided by the Network on
503 Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) for distribution through BEI
504 Resources (NR-48501). Deletions were confirmed by PCR and Sanger sequencing. Transposon
505 mutations sourced from the NTML were first confirmed by PCR and Sanger sequencing, then
506 transduced into *S. aureus* JE2 using phage φ11::FRT, as described previously (23, 24, 69).

507 Transductants were identified by antibiotic selection and confirmed by PCR and Sanger
508 sequencing.

509 In-frame unmarked gene deletions in *S. aureus* were generated by allelic exchange
510 using plasmid pIMAY*-Z and *E. coli* IM08B, as described previously (70–72). Complementation
511 plasmids were generated by amplifying the coding sequence of the gene and its native promoter
512 (approximately 200 bases preceding the coding sequence). Constructs were incorporated into
513 shuttle vector pOS1 by restriction-ligation cloning before being introduced to *E. coli* IM08B by
514 chemical transformation, followed by antibiotic selection. Inserts were confirmed by PCR and
515 Sanger sequencing. Plasmid DNA was extracted from *E. coli* IM08B and introduced to *S. aureus*
516 by electroporation and maintained by antibiotic selection.

517

518 **Sputum samples and sputum medium preparation**

519 Sputum samples were donated by pediatric patients being treated for CF at Seattle
520 Children's Hospital and stored at -80 °C until processing. No patient data were associated with
521 sputum samples for this study. To prepare growth media, frozen samples were thawed and
522 homogenized by probe sonication at a concentration of 10% (w/v) in either Staphylococcal
523 minimal medium with glucose and iron omitted (for Tn-seq) or SCFM buffered base (for CFU
524 growth assays)(20, 25). Media not used immediately were stored at -80 °C until use. The ability
525 of each medium to support growth of *S. aureus* JE2 was confirmed prior to inclusion of that
526 medium in Tn-seq or growth assays.

527

528 **Transposon library construction, sequencing, and analysis**

529 Plasmids pORF5-Tnp+, pORF5-Tnp-, and all transposon donor plasmids were a gift
530 from Timothy Meredith (24). Transposon mutagenesis was carried out as previously described
531 (24). Plasmids pORF5-Tnp+ (transposase-positive) and pORF5-Tnp- (transposase-negative
532 control) were introduced to the target strain *S. aureus* JE2 by electroporation and maintained by

533 antibiotic selection and growth at 30 °C. Transducing lysates were prepared with phage
534 $\phi 11::FRT$ from transposon donor strains carrying blunt, P_{cap} , P_{tuf} , P_{erm} , and P_{dual} transposon
535 variants. Each transposon construct was transduced into recipient strains JE2 pORF5-Tnp+ and
536 JE2 pORF5-Tnp-, and transposition efficiency was confirmed by comparing the frequency of
537 erythromycin-resistant colonies arising from the transposase-positive strain as compared to the
538 transposase-negative control strain. For each construct in JE2 pORF5-Tnp+, approximately 10^5
539 colonies were pooled, washed, and finally resuspended in TSB containing 20% glycerol for
540 storage at -80 °C. The transposition process was completed two independent times for a total of
541 ten libraries.

542 For Tn-seq, all libraries were thawed and pooled at equal volumes, then washed twice in
543 phosphate-buffered saline (PBS) and resuspended in PBS to $OD_{600} = 1.0$ (approximately 10^9
544 CFU/mL). Approximately 5×10^6 CFU were used to inoculate 1 mL of media in each of the
545 following 12 cultures: TSB; SCFM3; two cultures each of four individual SMM sputum media;
546 and two cultures of SMM sputum medium composed of all four individual media pooled in equal
547 volumes. Cultures were incubated at 37 °C with shaking at 200 rpm for 16 hours. CFU were
548 enumerated by spot plating immediately after inoculation and 16 hours post-inoculation. After 16
549 hours of growth, 100 μ L of each culture was used to inoculate 3 mL TSB. TSB subcultures were
550 incubated at 37 °C with shaking at 200 rpm for eight hours to expand biomass. 1 mL aliquots of
551 each TSB subculture were pelleted by centrifugation, the supernatant removed, and the cell
552 pellet stored at -80 °C until DNA extraction.

553 Genomic DNA was isolated from cell pellets by phenol/chloroform extraction followed by
554 ethanol precipitation. Libraries were prepared for sequencing as described previously (24). The
555 resulting library was sequenced by Northwest Genomics Center using an Illumina NextSeq
556 500/550 platform with a PhiX spike-in of 40%. Sequencing results were demultiplexed using
557 CutAdapt, aligned using bowtie2, and analyzed using TRANSIT (73–75). TRANSIT analysis

558 parameters are included in Tables S1 and S2. Set analyses were visualized in R using the
559 UpSetR package (76).

560

561 **Sputum growth assays**

562 To quantify mutant growth in sputum, approximately 10^9 bacterial cells were pelleted by
563 centrifugation, washed in PBS, and resuspended in PBS at an OD_{600} of 0.1 (approximately 10^8
564 CFU/mL). 2 μ L (2×10^5 CFU) of washed cells were used to inoculate 100 μ L of TSB or sputum
565 medium in a sterile polystyrene flat-bottom 96-well plate (Fisher). Plates were sealed with a
566 sterile gas-permeable membrane (Diversified Biotech) and lid and incubated at 37 °C with
567 shaking at 200 rpm for 12 hours. Immediately after inoculation and 12 hours post-inoculation,
568 cultures were mixed by pipetting and CFU enumerated by dilution plating.

569

570 **Bacterial growth curve assays**

571 Overnight bacterial cultures were washed in PBS and resuspended in PBS at an OD_{600}
572 of 1.0. 2 μ L of washed cells (2×10^6 CFU) were used to inoculate 200 μ L media in a flat-bottom
573 96-well plate with a gas-permeable membrane. Cysteine, glutathione, and N-acetylcysteine
574 solutions were prepared immediately prior to each experiment. Plates were incubated in a
575 BioTek Synergy HTX plate reader for 12 hours at 37 °C, with shaking, and growth was
576 measured by OD_{600} every ten minutes for the duration of the experiment.

577

578 **Calprotectin quantification**

579 Sputum (20% w/v) was treated with 0.1% DTT and mixed by pipetting or passing
580 through a sterile 25g needle until homogeneous. An equal volume of PBS was added for a final
581 sputum concentration of 10% (w/v). Debris was removed by centrifugation at 1200 rcf for 3
582 minutes followed by transfer of supernatant to a clean microcentrifuge tube. Calprotectin was
583 quantified using a Human Calprotectin ELISA kit (Abcam). The assay was performed two

584 independent times. Sputum supernatants were serially diluted in technical duplicate and all
585 dilutions whose calprotectin concentrations fell within the range of the assay were used to
586 compute the concentration of calprotectin in the undiluted sample. Calprotectin concentrations
587 were converted to molarity by approximating the density of unprocessed sputum as 1 g/mL.

588

589 **Transition metal quantification**

590 Transition metals were quantified by inductively coupled plasma mass spectrometry
591 (ICP-MS). Samples were digested in metal-free 15 mL conical tubes in 200 μ L 70% Optima-
592 grade nitric acid at 65°C overnight, then diluted with UltraPure water to 20% nitric acid for
593 analysis. Elemental quantification was conducted using an Agilent 7700 ICP-MS attached to an
594 ASX-560 autosampler. The settings for analysis were cell entrance = -40 V, cell exit = -60 V,
595 plate bias = -60 V, OctP bias = -18 V, and helium flow = 4.5 ml/min. Optimal voltages for extract
596 2, omega bias, omega lens, OctP RF, and deflect were empirically determined. Calibration
597 curves for elements were generated using ARISTAR ICP standard mix. Samples were
598 introduced by peristaltic pump with 0.5-mm-internal-diameter tubing through a MicroMist
599 borosilicate glass nebulizer. They were initially taken up at 0.5 rps for 30 seconds, followed by
600 30 seconds at 0.1 rps to stabilize the signal. Spectrum mode analysis was performed at 0.1 rps,
601 collecting three points across each peak and conducting three replicates of 100 sweeps for
602 each element. The sampling probe and tubing were rinsed with 2% nitric acid for 30 seconds at
603 0.5 rps between each sample. Data were acquired and analyzed using Agilent MassHunter
604 workstation software version A.01.02. Element quantities in parts per billion (ppb) were
605 converted to molarity by approximating the density of unprocessed sputum as 1 g/mL.

606

607 **Low-molecular-weight thiol profiling**

608 Sputum samples were resuspended to 10% sputum (w/v) in ultra-pure water. Samples
609 were homogenized by sonication using a Sonic Dismembrator 550 (Fisher Scientific) with a

610 microtip for one minute at maximum amplitude, 5.0 seconds on, 5.0 seconds off. To quantify
611 total LMW thiol content, 100 μ L of homogenized 10% sputum sample was mixed with TCEP in
612 excess for a final concentration of 5 mM TCEP and left to react at RT for 5 minutes to reduce
613 thiol disulfides. Samples were alkylated by addition of β -(4-hydroxyphenyl)ethyl iodoacetamide
614 (HPE-IAM) (Chem-Impex, Catalog #23038) in excess, for a final concentration of 5 mM HPE-
615 IAM in solution. Samples were incubated in a water bath at 37 °C for one hour. (77). Samples
616 were clarified by centrifugation and the supernatant was filtered through a 0.22 μ m spin filter
617 (Fisher Scientific, Catalog #07200389). Samples were mixed in a 1:1 ratio of solution containing
618 isotopically labeled standards of known concentration.

619 Alkylated standards were prepared using D_4 -HPE-IAM (Toronto Research Chemicals,
620 Catalog #1685882) as described (78). Samples were analyzed by LC using C18 (YMC-Triart
621 C18, 50 X 2.0 mm I.D., 1.9 μ m) with an attached guard column (Phenomenex, UHPLC C18-
622 Peptide, 2.1 mm I.D.), coupled to a Waters Synapt G2S mass spectrometer. Samples were run
623 using mobile phase A (0.25% acetic acid, 10% methanol) and mobile phase B (0.25% acetic
624 acid, 90% methanol) with the following LC elution gradient: 0-3 min, 100% A, 0% B; 3-7 min,
625 linear gradient to 75% A, 25% B; 7-9 min, 75% A, 25% B; 9-12 min, linear gradient to 25% A,
626 75% B; 12-14 min, linear gradient to 0% A, 100% B; 14-20 min, 0% A, 100% B. The resulting
627 total ion chromatogram (TIC) was searched for positively charged ions ($z = 1$; M^+ or $M + H^+$)
628 (mass tolerance of ± 0.02 Da) using Waters MassLynx software. The extracted ion
629 chromatograms (EIC) of each light (H_4) and heavy (D_4) HPE-IAM-capped thiols identified in MS1
630 were obtained and peak areas were quantified. The ratio of light and heavy MS1 features (rang,
631 0.01 to 500) was used to calculate the concentration of each thiol using the known
632 concentration of the heavy standard spiked into the mixture. All samples were run in technical
633 triplicate and the data determined in units of pmol thiol/mg sputum. We then converted these
634 data to μ M thiol, assuming a value of 1 mL/g sputum, a value slightly higher than a partial
635 specific volumes of protein (0.708 mL/g) or mucin (0.65 mL/g) (79).

636 **ACKNOWLEDGEMENTS**

637 This work was supported by Cystic Fibrosis Foundation (CFF) awards RENIERE2010
638 and SHULL22F0. Work in the Reniere lab is funded by NIH R01 AI132356. Work in the Hoffman
639 lab is funded by CFF grants SINGH19R0 and HOFFMA20Y2-OUT. Work in the Skaar lab is
640 funded by NIH R01s AI150701, AI1385, and AI073843. Work in the Giedroc lab is funded by
641 NIH R35 GM118157. The funders had no role in study design, data collection and interpretation,
642 or the decision to submit the work for publication. We thank Timothy Meredith for sharing
643 $\phi 11::FRT$, bacterial strains, and protocols. Finally, we thank members of the CF community and
644 their families for their participation in CF research, including this study.

645 REFERENCES

- 646 1. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S,
647 Plavsic N, Chou JL. 1989. Identification of the cystic fibrosis gene: cloning and
648 characterization of complementary DNA. *Science* 245:1066–1073.
- 649 2. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, Smith AE, Welsh
650 MJ. 1991. Demonstration That CFTR Is a Chloride Channel by Alteration of Its Anion
651 Selectivity. *Science* 253:202–205.
- 652 3. Bear CE, Li CH, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, Riordan JR. 1992.
653 Purification and functional reconstitution of the cystic fibrosis transmembrane conductance
654 regulator (CFTR). *Cell* 68:809–818.
- 655 4. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzky JT, Davis CW, Boucher RC. 1998.
656 Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the
657 pathogenesis of cystic fibrosis airways disease. *Cell* 95:1005–1015.
- 658 5. Boucher RC. 2007. Cystic fibrosis: a disease of vulnerability to airway surface dehydration.
659 *Trends in Molecular Medicine* 13:231–240.
- 660 6. Ciofu O, Hansen CR, Høiby N. 2013. Respiratory bacterial infections in cystic fibrosis.
661 *Current Opinion in Pulmonary Medicine* 19:251–258.
- 662 7. Cystic Fibrosis Foundation. 2022. Cystic Fibrosis Foundation Patient Registry 2022 Annual
663 Data Report.
- 664 8. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. 2008. Persistent
665 methicillin-resistant *Staphylococcus aureus* and rate of FEV1 decline in cystic fibrosis. *Am*
666 *J Respir Crit Care Med* 178:814–821.
- 667 9. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. 2010.
668 Association Between Respiratory Tract Methicillin-Resistant *Staphylococcus aureus* and
669 Survival in Cystic Fibrosis. *JAMA* 303:2386–2392.
- 670 10. Vanderhelst E, De Meirleir L, Verbanck S, Piérard D, Vincken W, Malfroot A. 2012.
671 Prevalence and impact on FEV(1) decline of chronic methicillin-resistant *Staphylococcus*
672 *aureus* (MRSA) colonization in patients with cystic fibrosis. A single-center, case control
673 study of 165 patients. *J Cyst Fibros* 11:2–7.
- 674 11. Esposito S, Pennoni G, Mencarini V, Palladino N, Peccini L, Principi N. 2019. Antimicrobial
675 Treatment of *Staphylococcus aureus* in Patients With Cystic Fibrosis. *Front Pharmacol*
676 10:849.
- 677 12. Zampoli M, Morrow BM, Paul G. 2023. Real-world disparities and ethical considerations with
678 access to CFTR modulator drugs: Mind the gap! *Front Pharmacol* 14:1163391.
- 679 13. Nichols DP, Morgan SJ, Skalland M, Vo AT, Van Daltsen JM, Singh SB, Ni W, Hoffman LR,
680 McGeer K, Heltshe SL, Clancy JP, Rowe SM, Jorth PK, Singh PK. 2023. Pharmacologic
681 improvement of CFTR function rapidly decreases sputum pathogen density but lung
682 infections generally persist. *J Clin Invest* e167957.

- 683 14. McCarron A, Parsons D, Donnelley M. 2021. Animal and Cell Culture Models for Cystic
684 Fibrosis: Which Model Is Right for Your Application? *The American Journal of Pathology*
685 191:228–242.
- 686 15. Semaniakou A, Croll RP, Chappe V. 2019. Animal Models in the Pathophysiology of Cystic
687 Fibrosis. *Frontiers in Pharmacology* 9:1475.
- 688 16. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland
689 RA, Wohlford-Lenane C, Dohrn CL, Bartlett JA, Nelson GA, Chang EH, Taft PJ, Ludwig
690 PS, Estin M, Hornick EE, Launspach JL, Samuel M, Rokhlina T, Karp PH, Ostedgaard LS,
691 Uc A, Starner TD, Horswill AR, Brogden KA, Prather RS, Richter SS, Shilyansky J, McCray
692 PB, Zabner J, Welsh MJ. 2010. Cystic fibrosis pigs develop lung disease and exhibit
693 defective bacterial eradication at birth. *Sci Transl Med* 2:29ra31.
- 694 17. Sun X, Sui H, Fisher JT, Yan Z, Liu X, Cho H-J, Joo NS, Zhang Y, Zhou W, Yi Y, Kinyon JM,
695 Lei-Butters DC, Griffin MA, Naumann P, Luo M, Ascher J, Wang K, Frana T, Wine JJ,
696 Meyerholz DK, Engelhardt JF. 2010. Disease phenotype of a ferret CFTR-knockout model
697 of cystic fibrosis. *J Clin Invest* 120:3149–3160.
- 698 18. Van Goor F, Straley KS, Cao D, González J, Hadida S, Hazlewood A, Joubran J, Knapp T,
699 Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH,
700 Tung R, Grootenhuys PDJ, Negulescu P. 2006. Rescue of $\Delta F508$ -CFTR trafficking and
701 gating in human cystic fibrosis airway primary cultures by small molecules. *American*
702 *Journal of Physiology-Lung Cellular and Molecular Physiology* 290:L1117–L1130.
- 703 19. Ulrich M, Herbert S, Berger J, Bellon G, Louis D, Münker G, Döring G. 1998. Localization of
704 *Staphylococcus aureus* in infected airways of patients with cystic fibrosis and in a cell
705 culture model of *S. aureus* adherence. *Am J Respir Cell Mol Biol* 19:83–91.
- 706 20. Palmer KL, Aye LM, Whiteley M. 2007. Nutritional Cues Control *Pseudomonas aeruginosa*
707 Multicellular Behavior in Cystic Fibrosis Sputum. *Journal of Bacteriology* 189:8079–8087.
- 708 21. Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M. 2015. Essential genome of
709 *Pseudomonas aeruginosa* in cystic fibrosis sputum. *Proceedings of the National Academy*
710 *of Sciences* 112:4110–4115.
- 711 22. Ibberson CB, Whiteley M. 2019. The *Staphylococcus aureus* Transcriptome during Cystic
712 Fibrosis Lung Infection. *mBio* 10:e02774-19.
- 713 23. Fey PD, Endres JL, Yajjala VK, Widhelm TJ, Boissy RJ, Bose JL, Bayles KW. 2013. A
714 genetic resource for rapid and comprehensive phenotype screening of nonessential
715 *Staphylococcus aureus* genes. *mBio* 4:e00537-00512.
- 716 24. Santiago M, Matano LM, Moussa SH, Gilmore MS, Walker S, Meredith TC. 2015. A new
717 platform for ultra-high density *Staphylococcus aureus* transposon libraries. *BMC Genomics*
718 16:252.
- 719 25. Machado H, Weng LL, Dillon N, Seif Y, Holland M, Pekar JE, Monk JM, Nizet V, Palsson
720 BO, Feist AM. 2019. Strain-Specific Metabolic Requirements Revealed by a Defined
721 Minimal Medium for Systems Analyses of *Staphylococcus aureus*. *Appl Environ Microbiol*
722 85:e01773-19.

- 723 26. Soutourina O, Poupel O, Coppée J-Y, Danchin A, Msadek T, Martin-Verstraete I. 2009.
724 CymR, the master regulator of cysteine metabolism in *Staphylococcus aureus*, controls
725 host sulphur source utilization and plays a role in biofilm formation. *Molecular Microbiology*
726 73:194–211.
- 727 27. Soutourina O, Dubrac S, Poupel O, Msadek T, Martin-Verstraete I. 2010. The Pleiotropic
728 CymR Regulator of *Staphylococcus aureus* Plays an Important Role in Virulence and
729 Stress Response. *PLOS Pathogens* 6:e1000894.
- 730 28. Ji Q, Zhang L, Sun F, Deng X, Liang H, Bae T, He C. 2012. *Staphylococcus aureus* CymR Is
731 a New Thiol-based Oxidation-sensing Regulator of Stress Resistance and Oxidative
732 Response. *J Biol Chem* 287:21102–21109.
- 733 29. Olson ME, King JM, Yahr TL, Horswill AR. 2013. Sialic acid catabolism in *Staphylococcus*
734 *aureus*. *J Bacteriol* 195:1779–1788.
- 735 30. Halsey CR, Lei S, Wax JK, Lehman MK, Nuxoll AS, Steinke L, Sadykov M, Powers R, Fey
736 PD. 2017. Amino Acid Catabolism in *Staphylococcus aureus* and the Function of Carbon
737 Catabolite Repression. *mBio* 8:10.1128/mbio.01434-16.
- 738 31. Ding X, Robbe-Masselot C, Fu X, Léonard R, Marsac B, Dauriat CJG, Lepissier A, Rytter H,
739 Ramond E, Dupuis M, Euphrasie D, Dubail I, Schimmich C, Qin X, Parraga J, Leite-de-
740 Moraes M, Ferroni A, Chassaing B, Sermet-Gaudelus I, Charbit A, Coureuil M, Jamet A.
741 2023. Airway environment drives the selection of quorum sensing mutants and promote
742 *Staphylococcus aureus* chronic lifestyle. 1. *Nat Commun* 14:8135.
- 743 32. Grunenwald CM, Choby JE, Juttukonda LJ, Beavers WN, Weiss A, Torres VJ, Skaar EP.
744 2019. Manganese Detoxification by MntE Is Critical for Resistance to Oxidative Stress and
745 Virulence of *Staphylococcus aureus*. *mBio* 10:e02915-18.
- 746 33. Sitthisak S, Knutsson L, Webb JW, Jayaswal RK. 2007. Molecular characterization of the
747 copper transport system in *Staphylococcus aureus*. *Microbiology* 153:4274–4283.
- 748 34. Chen C, Hooper DC. 2019. Intracellular Accumulation of Staphylopin Impairs the Fitness of
749 *Staphylococcus aureus* cntE Mutant. *FEBS Lett* 593:1213–1222.
- 750 35. Grim KP, Radin JN, Solórzano PKP, Morey JR, Frye KA, Ganio K, Neville SL, McDevitt CA,
751 Kehl-Fie TE. 2020. Intracellular Accumulation of Staphylopin Can Sensitize
752 *Staphylococcus aureus* to Host-Imposed Zinc Starvation by Chelation-Independent
753 Toxicity. *Journal of Bacteriology* 202:10.1128/jb.00014-20.
- 754 36. Ghssein G, Brutesco C, Ouerdane L, Fojcik C, Izaute A, Wang S, Hajjar C, Lobinski R,
755 Lemaire D, Richaud P, Voulhoux R, Espallat A, Cava F, Pignol D, Borezée-Durant E,
756 Arnoux P. 2016. Biosynthesis of a broad-spectrum nicotianamine-like metallophore in
757 *Staphylococcus aureus*. *Science* 352:1105–1109.
- 758 37. Akanuma G, Kawamura F, Watanabe S, Watanabe M, Okawa F, Natori Y, Nanamiya H, Asai
759 K, Chibazakura T, Yoshikawa H, Soma A, Hishida T, Kato-Yamada Y. 2021. Evolution of
760 Ribosomal Protein S14 Demonstrated by the Reconstruction of Chimeric Ribosomes in
761 *Bacillus subtilis*. *J Bacteriol* 203:e00599-20.

- 762 38. Kochan I. 1973. The Role of Iron in Bacterial Infections, with Special Consideration of Host-
763 Tubercle Bacillus Interaction, p. 1–30. *In* Arber, W, Braun, W, Haas, R, Henle, W,
764 Hofschneider, PH, Jerne, NK, Koldovský, P, Koprowski, H, Maaløe, O, Rott, R, Schweiger,
765 HG, Sela, M, Syruček, L, Vogt, PK, Wecker, E (eds.), *Current Topics in Microbiology and*
766 *Immunology*. Springer, Berlin, Heidelberg.
- 767 39. Weinberg ED. 1975. Nutritional Immunity: Host's Attempt to Withhold Iron From Microbial
768 Invaders. *JAMA* 231:39–41.
- 769 40. Hood MI, Skaar EP. 2012. Nutritional immunity: transition metals at the pathogen–host
770 interface. *Nat Rev Microbiol* 10:525–537.
- 771 41. Grim KP, San Francisco B, Radin JN, Brazel EB, Kelliher JL, Párraga Solórzano PK, Kim
772 PC, McDevitt CA, Kehl-Fie TE. 2017. The Metallophore Staphylopin Enables
773 *Staphylococcus aureus* To Compete with the Host for Zinc and Overcome Nutritional
774 Immunity. *mBio* 8:e01281-17.
- 775 42. Grim KP. 2020. Elucidating the mechanisms by which the human pathogen *staphylococcus*
776 *aureus* resists host-imposed zinc starvation. Thesis. University of Illinois at Urbana-
777 Champaign.
- 778 43. Boyd JM, Esquilín-Lebrón K, Campbell CJ, Kaler KR, Norambuena J, Foley ME, Stephens
779 TG, Rios G, Mereddy G, Zheng V, Bovermann H, Kim J, Kulczyk AW, Yang JH, Greco TM,
780 Cristea IM, Carabetta VJ, Beavers WN, Bhattacharya D, Skaar EP, Parker D, Carroll RK,
781 Stemmler TL. 2023. YlaN is an iron(II) binding protein that functions to relieve Fur-
782 mediated repression of gene expression in *Staphylococcus aureus*. *bioRxiv*
783 <https://doi.org/10.1101/2023.10.03.560778>.
- 784 44. Sebulsky MT, Hohnstein D, Hunter MD, Heinrichs DE. 2000. Identification and
785 characterization of a membrane permease involved in iron-hydroxamate transport in
786 *Staphylococcus aureus*. *J Bacteriol* 182:4394–4400.
- 787 45. Dale SE, Sebulsky MT, Heinrichs DE. 2004. Involvement of SirABC in Iron-Siderophore
788 Import in *Staphylococcus aureus*. *Journal of Bacteriology* 186:8356–8362.
- 789 46. Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, Anderson KL, Dattilo BM,
790 Dunman PM, Gerads R, Caprioli RM, Nacken W, Chazin WJ, Skaar EP. 2008. Metal
791 Chelation and Inhibition of Bacterial Growth in Tissue Abscesses. *Science* 319:962–965.
- 792 47. Nakashige TG, Zhang B, Krebs C, Nolan EM. 2015. Human Calprotectin Is an Iron-
793 Sequestering Host-Defense Protein. *Nat Chem Biol* 11:765–771.
- 794 48. Besold AN, Gilston BA, Radin JN, Ramsoomair C, Culbertson EM, Li CX, Cormack BP,
795 Chazin WJ, Kehl-Fie TE, Culotta VC. 2018. Role of Calprotectin in Withholding Zinc and
796 Copper from *Candida albicans*. *Infect Immun* 86:e00779-17.
- 797 49. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. 2010. Sputum and serum
798 calprotectin are useful biomarkers during CF exacerbation. *Journal of Cystic Fibrosis*
799 9:193–198.

- 800 50. Dauletbaev N, Viel K, Buhl R, Wagner TOF, Bargon J. 2004. Glutathione and glutathione
801 peroxidase in sputum samples of adult patients with cystic fibrosis. *J Cyst Fibros* 3:119–
802 124.
- 803 51. Lensmire JM, Wischer MR, Kraemer-Zimpel C, Kies PJ, Sosinski L, Ensink E, Dodson JP,
804 Shook JC, Delekta PC, Cooper CC, Havlichek DH, Mulks MH, Lunt SY, Ravi J, Hammer
805 ND. 2023. The glutathione import system satisfies the *Staphylococcus aureus* nutrient
806 sulfur requirement and promotes interspecies competition. *PLoS Genet* 19:e1010834.
- 807 52. Lensmire JM, Dodson JP, Hsueh BY, Wischer MR, Delekta PC, Shook JC, Ottosen EN, Kies
808 PJ, Ravi J, Hammer ND. 2020. The *Staphylococcus aureus* Cystine Transporters TcyABC
809 and TcyP Facilitate Nutrient Sulfur Acquisition during Infection. *Infect Immun* 88:e00690-
810 19.
- 811 53. Blix G, Lindberg E, Odin L, Werner I. 1955. Sialic Acids. *Nature* 175:340–341.
- 812 54. Ding X, Robbe-Masselot C, Fu X, Léonard R, Marsac B, Dauriat CJG, Lepissier A, Rytter H,
813 Ramond E, Dupuis M, Euphrasie D, Dubail I, Schimmich C, Qin X, Parraga J, Leite-de-
814 Moraes M, Ferroni A, Chassaing B, Sermet-Gaudelus I, Charbit A, Coureuil M, Jamet A.
815 2023. Airway environment drives the selection of quorum sensing mutants and promote
816 *Staphylococcus aureus* chronic lifestyle. 1. *Nat Commun* 14:8135.
- 817 55. Byers HL, Tarelli E, Homer KA, Beighton D. 2000. Isolation and characterisation of sialidase
818 from a strain of *Streptococcus oralis*. *J Med Microbiol* 49:235–244.
- 819 56. Beighton D, Whiley RA. 1990. Sialidase activity of the “*Streptococcus milleri* group” and
820 other viridans group streptococci. *J Clin Microbiol* 28:1431–1433.
- 821 57. Moncla BJ, Braham P. 1989. Detection of sialidase (neuraminidase) activity in *Actinomyces*
822 species by using 2’-(4-methylumbelliferyl)alpha-D-N-acetylneuraminic acid in a filter paper
823 spot test. *J Clin Microbiol* 27:182–184.
- 824 58. Moncla BJ, Braham P, Rabe LK, Hillier SL. 1991. Rapid presumptive identification of black-
825 pigmented gram-negative anaerobic bacteria by using 4-methylumbelliferone derivatives. *J*
826 *Clin Microbiol* 29:1955–1958.
- 827 59. Reyes Ruiz VM, Freiberg JA, Weiss A, Green ER, Jobson M-E, Felton E, Shaw LN, Chazin
828 WJ, Skaar EP. 2024. Coordinated adaptation of *Staphylococcus aureus* to calprotectin-
829 dependent metal sequestration. *mBio* 0:e01389-24.
- 830 60. Lewin GR, Kapur A, Cornforth DM, Duncan RP, Diggle FL, Moustafa DA, Harrison SA,
831 Skaar EP, Chazin WJ, Goldberg JB, Bomberger JM, Whiteley M. 2023. Application of a
832 quantitative framework to improve the accuracy of a bacterial infection model. *Proceedings*
833 *of the National Academy of Sciences* 120:e2221542120.
- 834 61. Sørensen MA, Pedersen S. 1991. Cysteine, even in low concentrations, induces transient
835 amino acid starvation in *Escherichia coli*. *Journal of Bacteriology* 173:5244–5246.
- 836 62. Kari C, Nagy Z, Kovács P, Hernádi F. 1971. Mechanism of the Growth Inhibitory Effect of
837 Cysteine on *Escherichia coli*. *Microbiology* 68:349–356.

- 838 63. Park S, Imlay JA. 2003. High levels of intracellular cysteine promote oxidative DNA damage
839 by driving the fenton reaction. *J Bacteriol* 185:1942–1950.
- 840 64. Kehl-Fie TE, Zhang Y, Moore JL, Farrand AJ, Hood MI, Rathi S, Chazin WJ, Caprioli RM,
841 Skaar EP. 2013. MntABC and MntH Contribute to Systemic *Staphylococcus aureus*
842 Infection by Competing with Calprotectin for Nutrient Manganese. *Infect Immun* 81:3395–
843 3405.
- 844 65. Handke LD, Gribenko AV, Timofeyeva Y, Scully IL, Anderson AS. 2018. MntC-Dependent
845 Manganese Transport Is Essential for *Staphylococcus aureus* Oxidative Stress Resistance
846 and Virulence. *mSphere* 3:10.1128/msphere.00336-18.
- 847 66. Pané-Farré J, Jonas B, Förstner K, Engelmann S, Hecker M. 2006. The σ B regulon in
848 *Staphylococcus aureus* and its regulation. *International Journal of Medical Microbiology*
849 296:237–258.
- 850 67. Pané-Farré J, Jonas B, Hardwick SW, Gronau K, Lewis RJ, Hecker M, Engelmann S. 2009.
851 Role of RsbU in Controlling SigB Activity in *Staphylococcus aureus* following Alkaline
852 Stress. *J Bacteriol* 191:2561–2573.
- 853 68. Long DR, Wolter DJ, Lee M, Precit M, McLean K, Holmes E, Penewit K, Waalkes A,
854 Hoffman LR, Salipante SJ. 2021. Polyclonality, Shared Strains, and Convergent Evolution
855 in Chronic Cystic Fibrosis *Staphylococcus aureus* Airway Infection. *Am J Respir Crit Care*
856 *Med* 203:1127–1137.
- 857 69. Olson ME. 2016. Bacteriophage Transduction in *Staphylococcus aureus*, p. 69–74. *In* Bose,
858 JL (ed.), *The Genetic Manipulation of Staphylococci: Methods and Protocols*. Springer,
859 New York, NY.
- 860 70. Monk IR, Tree JJ, Howden BP, Stinear TP, Foster TJ. 2015. Complete Bypass of Restriction
861 Systems for Major *Staphylococcus aureus* Lineages. *mBio* 6:e00308-00315.
- 862 71. Monk IR, Stinear TPY 2021. 2021. From cloning to mutant in 5 days: rapid allelic exchange
863 in *Staphylococcus aureus*. *Access Microbiology* 3:000193.
- 864 72. Schuster CF, Howard SA, Gründling A 2019. 2019. Use of the counter selectable marker
865 PheS* for genome engineering in *Staphylococcus aureus*. *Microbiology* 165:572–584.
- 866 73. Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing
867 reads. 1. *EMBnet.journal* 17:10–12.
- 868 74. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
869 9:357–359.
- 870 75. DeJesus MA, Ambadipudi C, Baker R, Sasseti C, Ioeinger TR. 2015. TRANSIT - A Software
871 Tool for Himar1 TnSeq Analysis. *PLOS Computational Biology* 11:e1004401.
- 872 76. Conway JR, Lex A, Gehlenborg N. 2017. UpSetR: an R package for the visualization of
873 intersecting sets and their properties. *Bioinformatics* 33:2938–2940.

- 874 77. Zhang Y, Gonzalez-Gutierrez G, Legg KA, Walsh BJC, Pis Diez CM, Edmonds KA, Giedroc
875 DP. 2022. Discovery and structure of a widespread bacterial ABC transporter specific for
876 ergothioneine. *Nat Commun* 13:7586.
- 877 78. Abo M, Li C, Weerapana E. 2018. Isotopically-Labeled Iodoacetamide-Alkyne Probes for
878 Quantitative Cysteine-Reactivity Profiling. *Mol Pharmaceutics* 15:743–749.
- 879 79. Thornton DJ, Sheehan JK, Lindgren H, Carlstedt I. 1991. Mucus glycoproteins from cystic
880 fibrotic sputum. Macromolecular properties and structural “architecture”. *Biochem J*
881 276:667–675.
- 882